Darwin, development, Drosophila, and disease
John P. Iredale – 23 December 2009
Protection of mitochondrial genome integrity: A new stem cell property?
Malcolm R. Alison, Stuart A. C. McDonald, Wey Ran Lin, Nicholas A. Wright – 23 December 2009
Statins and hepatitis C virus: Friend or foe?
Enzo Emanuele – 23 December 2009
Limitations of the algorithm for the SAFE biopsy: A noninvasive fibrosis measure in chronic hepatitis C
Mohammed Rashid, Jonathon D. Mitchell, Matthew E. Cramp, Timothy J. S. Cross – 23 December 2009
Supporting evidence for natural killer T cell accumulation in progressive nonalcoholic fatty liver disease?
Wing‐Kin Syn, Ye Htun Oo – 23 December 2009
Liver injury in acute fatty liver of pregnancy: Possible link to placental mitochondrial dysfunction and oxidative stress
Sathish Kumar Natarajan, Kavitha R. Thangaraj, C. E. Eapen, Anup Ramachandran, Ashis Mukhopadhya, Mathews Mathai, Lakshmi Seshadri, Abraham Peedikayil, Banumathi Ramakrishna, Kunnissery A. Balasubramanian – 23 December 2009 – Acute fatty liver of pregnancy (AFLP) is a rare disorder which is fatal if not recognized and treated early. Delivery of the feto‐placental unit results in dramatic improvement in maternal liver function, suggesting a role for the placenta.
Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation
José A. Carrión, Ferran Torres, Gonzalo Crespo, Rosa Miquel, Juan‐Carlos García‐Valdecasas, Miquel Navasa, Xavier Forns – 23 December 2009 – Significant liver fibrosis (F ≥ 2) and portal hypertension (hepatic venous pressure gradient [HVPG] ≥ 6 mmHg) at 1 year after liver transplantation (LT) identify patients with severe hepatitis C recurrence. We evaluated whether repeated liver stiffness measurements (LSM) following LT can discriminate between slow and rapid “fibrosers” (fibrosis stage F2‐F4 at 1 year after LT).
Emphysematous gastritis in a liver transplant recipient
Muhammad F. Dawwas, Rajesh Sivaprakasam, Andrew J. Butler, Neville V. Jamieson, Graeme J. Alexander – 23 December 2009
Are recipients of solid organ transplantation a high‐risk population for hepatitis E virus infection?
Maria Buti, Cecilia Cabrera, Rosendo Jardi, Luis Castells, Rafael Esteban – 23 December 2009
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Kittichai Promrat, David E. Kleiner, Heather M. Niemeier, Elizabeth Jackvony, Marie Kearns, Jack R. Wands, Joseph L. Fava, Rena R. Wing – 23 December 2009 – Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity. Currently, there is no approved therapy for NASH. Weight reduction is typically recommended, but efficacy data are lacking.